Kinases Bicker Over an Ion Channel

Reddy, Smitha

doi:10.1523/jneurosci.4133-05.2006

Cited by 2 publications

(1 citation statement)

References 5 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Activation of small conductance K + channels is blocked in the presence of the PKG inhibitor KT-5823, indicating that PKG can act on small conductance K + channels. This suggests that neuronal events such as repolarization may be mediated by the presence of PKG via the phosphorylation of K + channels (Reddy, 2006). Inhibition of PKG using a specific inhibitor such as KT-5823 could therefore prevent, or decrease, the rate of K + channel phosphorylation.…”

Section: Pkg Signallingmentioning

confidence: 99%

Nitrergic modulation of an oviposition digging rhythm in locusts

Newland

Yates

2007

Journal of Experimental Biology

View full text Add to dashboard Cite

with ODQ reduced the cycle frequency of the rhythm, suggesting that NO mediated its effects via sGC and cyclic GMP. Further evidence for this was produced by bath application of 8-Br-cGMP, which increased the frequency of the rhythm. Bath application of the generic protein kinase inhibitor and a selective PKG inhibitor, H-7 and KT-5823, respectively, reduced the frequency of the rhythm, suggesting that PKG acted as a target for cGMP. Thus, we conclude that NO plays a key role in regulating the frequency of the central pattern generator controlling rhythmic egg-laying movements in locusts by acting via sGC/cGMP-PKG.

show abstract

Section: Pkg Signallingmentioning

confidence: 99%

Nitrergic modulation of an oviposition digging rhythm in locusts

Newland

Yates

2007

Journal of Experimental Biology

View full text Add to dashboard Cite

show abstract

New therapeutic options for musculoskeletal pain

Данилов

Коржавина

2019

Med. sov.

View full text Add to dashboard Cite

Musculoskeletal pain (MSP) is one of the major interdisciplinary problems of modern medicine and society. Inflammation is a universal mechanism that plays a crucial role in the development of acute and chronic MSP. Therefore, non-steroidal antiinflammatory drugs (NSAIDs) are the first-line treatment for MSP. The effectiveness of all NSAIDs in reducing pain and inflammation is approximately the same, and the degree of safety is determined by their relationship to COX-1 and COX-2 enzymes. Thanks to pharmacological properties and a balanced profile of efficiency and safety, the successful position of the «golden mean» between cokebins and non-selective NSAIDs is a moderately selective aceklofenac, which makes it appropriate for the vast majority of patients with MSP. Introduction into clinical practice of the drug Aceklagin containing 200 mg of aceсlofenaс in a new drug form with modified two-phase release, opens up new possibilities of MSP therapy. Due to the stable concentration of aceclofenac in the body during the day, Aceklagin improves the efficiency of pain and inflammation treatment in patients with MSP, while maintaining a high level of safety inherent in this molecule.

show abstract

Kinases Bicker Over an Ion Channel

Cited by 2 publications

References 5 publications

Nitrergic modulation of an oviposition digging rhythm in locusts

Nitrergic modulation of an oviposition digging rhythm in locusts

New therapeutic options for musculoskeletal pain

Contact Info

Product

Resources

About